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Purpose. The long-term eﬃcacy of carotid artery stenting is debated. Predictors of stent restenosis are not fully investigated. Our
aim was to assess the incidence of long term restenosis after CAS and to identify some predictors of restenosis. Methods.W e
retrospectively selected 189 treated patients and we obtained the survival Kaplan-Meier curves for overall survival, for freedom
from stroke or death and from restenosis. To correlate clinical, radiological, and procedural variables to stent restenosis, an
univariate analysis was performed while to determine independent predictors of restenosis, a multivariate analysis was applied.
Results. At 1, 3, and 5 years, the cumulative overall survival rate was 98%, 94%, and 92% with a cumulative primary patency
rate of 87%, 82.5%, and 82.5%. The percentage residual stenosis after CAS and multiple stents deployment were independent
predictors of restenosis, while diabetes and tumors are suggestive but not signiﬁcant predictors of restenosis. Conclusions.I no u r
CAS experience, encouraging long-term results seem to derive from both neurological event free rate and restenosis incidence.
Adequate recanalization of the treated vessel is important to limit the development of stent restenosis. Multiple stents deployment,
and with less evidence, diabetes, or neoplasms has to be considered to facilitate restenosis.
1.Introduction
Based upon data of multicenter trials, carotid endarterec-
tomy (CEA) is a proven treatment in carotid artery stenosis
and it is considered the most eﬀective method to prevent
stroke occurrence in patients with symptomatic and asymp-
tomatic high-grade carotid artery disease [1, 2]. For high risk
surgical patients, percutaneous carotid transluminal angio-
plasty and stenting (CAS) are emerging with encouraging
results as alternative method to carotid endarterectomy [3].
The endovascular treatment of carotid artery stenosis
with CAS has an acceptable periprocedural complication
rate and stroke/death rate at one year especially with the
u s eo fc e r e b r a lp r o t e c t i o nd e v i c e s[ 4–6]. On the basis
of randomized [3] and non randomized [7]m u l t i c e n t e r
trials results, in high surgical risk patients, protected CAS
is actually considered equal to surgery in the hands of
experienced operators [8].
TheeﬃcacyofCASovertimeisunderclinicalevaluation.
Data regarding eﬃcacy of CAS over a longer period of time
(until ﬁve years) are recently emerging [9]. In a recent meta-
analysis [10] the early restenosis rates after CAS compare
well with those reported for CEA, nevertheless due to the
short followup period of many published works the long
term durability of CAS needs of further studies. Moreover
few information are available about independent clinical,
radiological or procedural predictors of restenosis after CAS
in patients with long followup.
The aim of our study was to assess the incidence of
long term in-stent restenosis after CAS and to identify some
clinical, radiological or procedural predictors of restenosis.
2.MaterialsandMethods
2.1. Patients Selection and Data Collection. We conduct a
retrospective study including patients that underwent CAS2 Stroke Research and Treatment
in our centre from 1997 to 2004. Out of 400 procedures we
select from our data base 189 patients that underwent to
a complete clinical and CD-US followup exclusively in our
centre avoiding to include patients that were followed from
other hospitals and operators. Previously, we have obtained
for this study the approval from our Istitutional Review
Board. Indications to CAS were ICA stenosis higher than
70% in symptomatic patients and asymptomatic patients
with one of the following co-morbidities: two or more coro-
nary vessels with >70% stenosis, an ejection fraction <30%,
bronchopulmonary obstructive disease, recurrent stenosis
afterCEA,previousradicalnecksurgeryorradiationtherapy,
surgicallyinaccessiblelesionsandcontrolateralcarotidartery
occlusion. Diagnosis of ICA stenosis was made by CD-US
and by MRA or CTA as a conﬁrmatory test and deﬁnitively
stated with DSA.
One hundred forty eight patients were males and 41
females with a mean age of 72.31 ± 8.17 (range 37–87 y).
200 vessels were treated with CAS (in 11 patients (5.8%)
a bilateral treatment was performed). In 169 vessels the
carotid stenosis was atherosclerotic (84.5%), in 23 it was
postsurgical (restenosis after endarterectomy) (11.5%) and
in 8 post radiotherapy (4%). Ninety eight vessels (49%) did
not causeneurological ipsilateral symptoms while 102 (51%)
did it.
Clinical, radiological and procedural data supposed to
interfere with in-stent restenosis were collected. Clinical
variables included age, sex, symptomatic status of patient,
and presence of supposed risk factors and comorbidity
(smoke, chronic pulmonary diseases, hypertension, diabetes,
hypercholesterolemia, coronary arterial disease, neoplasms).
Radiological variables were obtained with the evaluation
of pre and post-procedural diagnostic DSA. They included
the grade of stenosis, presence of ulcerated plaques, nature
of stenosis (atherosclerotic versus not atherosclerotic), per-
centage of residual stenosis after CAS. Procedural variables
included postdilatation, type of stent, number of deployed
stents.
2.2. CAS Procedure. A l lp r o c e d u r e sw e r ep e r f o r m e dw i t h
local anesthesia and percutaneous transfemoral access F8.
Patients were premedicated with aspirin (100mg/die)
and ticlopidine (500mg die) at least three days preinterven-
tion.
The patients received intra-arterial administration of
70IU/Kg of heparin to achieve an activated clotting time
(ACT) longer than 200–250 sec. By using a 100-cm long
guiding catheter, the ﬁlter guidewire was introduced crossing
the stenosis and the cerebral protection device, a self-
expanding basket type ﬁlter, was deployed in the cervical
portion of internal carotid artery. Out of 200 procedures, 69
(34.5%) were performed with a cerebral protection device
(Filter Wire EZ Boston Scientiﬁc). A self-expandable stent
was mounted on the protection device guidewire and placed
and deployed across the stenosis. In our study group the
type of stent in the 200 procedure was: 132 (66%) Carotid
WallStent Monorail (Boston Scientiﬁc), 39 (19.5%) Precise
Stent (Cordis Corp., Johnson & Johnson Company), 17 (8.5%)
Easy WallStent (Boston Scientiﬁc), 7 (3.5%) Smart Stent
(Cordis Corp., Johnson & Johnson Company), 3 (1.5%) Wall-
stent (Boston Scientiﬁc Corp.), 1 (0.5%) Acculink (Guidant
Corp), 1 (0.5%) Omnilink (Guidant Corp). The stent was
dilated to reach an adequate vessel recanalization by using
an appropriate size angioplasty balloon. One mg of atropine
sulphate was intravenously administered during angioplasty
ballooninsuﬄationstopreventcarotidsinusstimulationand
bradycardia. Then the cerebral protection device, when used,
was removed. Predilation with a 3mm PTA balloon catheter
(generally Ultrasoft 5V Boston Scientiﬁc Natick MA USA)
was performed in 34 patients before stent placement in tight
stenoses with a residual lumen smaller than the diameter of
the stent delivery catheter.
In 19 patients the misplacement of the ﬁrst stent
necessitates of the deployment of a further stent.
A permanent daily medication with acetylsalicylic acid
(100mg) and a prevention therapy with 500mg/die of
ticlopidine was started for one month, after endovascular
recanalization.
Before the interventional procedure, all patients were
submitted to diagnostic DSA by selective injection of both
common carotid arteries and vertebral arteries of at least one
side. Intracranial vessels and carotid bifurcation evaluation
ofthetreatedsidewasrepeatedafterendovascularprocedure.
In case of unprotected CAS, the procedure diﬀered
exclusively for use of guidewire instead of ﬁlter guidewire
to encompass the stenosis. Patients remained in a monitored
setting overnight and discharged in the following day.
2.3. CD-US Follow-Up. All patients were followed with CD-
US examination at 24 hours, 1, 3, 6 months after the
procedure and every 6 months thereafter. In each diagnostic
session a clinical interview was made. The restenosis detec-
tion was based on CD-US by using modiﬁed velocity criteria
of Washington University [11] developed in our centre and
validated with digital subtraction angiography. Moreover B-
mode imaging of the arterial lumen and spectral waveform
analysis were used to assess possible restenosis occurrence.
Elevations in peak systolic velocity or ICA/CCA ratio with
respect to the ﬁrst post procedural CD-US examination were
considered as suggestive of progressive in-stent restenosis. A
peak systolic velocity higher than 220cm/sec was interpreted
as a stenosis higher than 50%.
A in stent stenosis higher than 50% was considered a
restenosis.
2.4. Statistical Analysis. Continuous data are presented as
mean value±SD, and categorical data are presented as
frequencies.
Overall survival curves (Kaplan-Meier) were obtained
using as end point, respectively, death, occurrence of major
relatedevent(deathandstroke)andoccurrenceofrestenosis.
Patientsdeadfornonrelatedcauseswereconsideredaslostto
the observation.
Clinical, radiological and procedural variables were
used as group variables in an univariate survival analysis
(Kaplan-Meier, log-rank Mantel Cox test for signiﬁcance of
diﬀerence).Thisanalysiswasperformedbypatient(n = 189)Stroke Research and Treatment 3
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Figure 1: Kaplan Meyer analysis curve of the cumulative freedom
from stroke and death.
relative to the clinical variables and by vessel (n = 200)
relative to the radiological and procedural variables.
Finally a multivariate survival analysis was performed
by using the proportional hazard stepwise Cox model (P to
enter = .15). This analysis was performed by patient and
excluding the single patient bilaterally treated with a single
vesselrestenosis(n = 188).Statisticalanalysiswasperformed
with Stat View 5.02 software package (Abacus Concepts).
3. Results
All patients were observed for a mean of 29.9 months
(range 0–99) median 26 months. The overall periprocedural
complicationswere5(2.6%):2fatalstrokes(1.05%),1major
stroke (0.5%) and 2 minor strokes (1.05%).
The overall survival rate was 98% at 1 year, 94% at 3,
and 92% at 5 years. The freedom from stroke and death
deﬁned as the freedom from all ipsilateral strokes and related
deaths, was 95.1% at one year, 91.4% at 3 years and 89.1%
at ﬁve years from treatment (Figure 1). During the followup
we observed 5 periprocedural complications and 9 further
strokes (4.8%), all of them were homolateral to the treated
vessel. Out of 9 patients with stroke, 7 deceased (3.7%).
Twenty-three patients for a total of 23 treated ves-
sels (23/200, 11.5%) developed a in-stent restenosis. Six
restenosis occurred after stenting of 31 not-atherosclerotic
plaques while 17 restenosis followed the stenting of 169
atherosclerotic stenosis. Restenosis occurred proximally to
the stent implantation (common carotid artery) in four
vessels, distally to the stent implantation (internal carotid
artery) in one, and in the middle segment of the stent
in 18 vessels. The grading of the restenosis was moderate
(50%–79%) in 18 vessels (18/200, 9%), and severe (>80%)
in 5 vessels (5/200, 2.5%). Only three patients (3/23, 12%)
had a neurological event homolateral to the treated and
restenosed vessel. The remaining patients with restenosis
were asymptomatic. The cumulative rate of freedom from
restenosis was, respectively, of 87%, 82.5% and 82.5%,
respectively, at 1, 3 and 5 years (Figure 2).
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Figure 2: Kaplan Meyer analysis curve of the cumulative freedom
from restenosis.
Out of 23 restenosis, 10 were retreated with angioplasty
alone (7 restenosis) or combined angioplasty and stenting
(3 restenosis). In one patient with restenosis the intention
to treat failed for the highly deformed stent that did not
permit the crossing of the stenosis with the angioplasty
balloon catheter. In three cases the treatment of restenosis
was performed with a cerebral protection device placement.
No periprocedural complications occurred in all retreated
patients.
T h ec u m u l a t i v er a t eo fs u r v i v a ld i dn o td i ﬀer from
patients with restenosis with respect to patients without it
(P = .48). The comparison of the Kaplan-Meyer curves
in patients with and without restenosis does not reveal a
signiﬁcant diﬀerence (P = .37) in the free neurological event
rate (Figure 3) that was 95%, 80% and 80% in the ﬁrst group
with respect to 95%, 93% and 90% in the latter, respectively
a t1 ,3a n d5y e a r s .
Out of all the clinical radiological and procedural
variables, the univariate analysis revealed that residual
stenosis after stenting and the number of deployed stents
for lesion are the only variables that correlate with the
restenosis occurrence (P = .0007 and P = .04,
resp.).
Multivariate analysis showed that the residual stenosis
after stenting is a positive predictor of restenosis with relative
hazard 1.091 per percent unit of residual stenosis, (CI 95%
1.050–1.130) P<. 0001.
Another signiﬁcant predictors was double stent deploy-
ment with relative hazard 5.2, (CI 95% 1.49–18.5) P =
.0084. Suggestive but not signiﬁcant variables, included in
thestepwisemodel,werediabeteswithrelativehazard2.30,P
value = .070 and neoplasms with relative hazard2.53,P value
= .085.
4. Discussion
The overall periprocedural complications in our series are
comparable to the literature results [4] and within the range
of the acceptable perioperative risks after CEA [12].4 Stroke Research and Treatment
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Figure 3: Kaplan Meyer analysis curves of the cumulative freedom
from stroke and death in patients with (dotted line) and without
(continuous line) restenosis.
The stroke or death rate (4.9% at one year, 8.6% at 3
years and 10.9% at ﬁve years from treatment) is in line
with former publications that report 4%–7% at one year
[9,13,14],10.1%–11%at3years[9,15]and15.1%at5years
[9] indicating encouraging prospective for CAS also over a
long period of time.
The overall incidence of restenosis >50% is 11.5% and
it is comparable to the value reported for CEA (10%) at
one year [16] and lower to 20% at one year of angioplasty
alone [17] conﬁrming the competitiveness of CAS and CEA
and the improvement of angioplasty durability after a stent
deployment. Our cumulative restenosis rate at one and two
years is 13 and 13.8%, respectively, slightly higher to the
values derived from a recent meta-analysis (6 and 7.5% at
one and two years) [10] but within the range reported in
the literature varying from 0.6% [18] to 20.8% [19]. If we
consider a signiﬁcant restenosis as higher to 80%, we obtain
an overall incidence of restenosis of 2.5% that is lower to the
4%reportedintheaforementionedmeta-analysisstudy[10].
Lower restenosis rate are reported in the single long-term
multi-centrestudyofELOCAregistry[9](1%,2%and3.4%,
resp. to 1, 3 and 5 years). The variable incidence of restenosis
in the diﬀerent centres means that restenosis is not however
negligible and it induce us to monitor the patients submitted
to CAS over time.
We outline that the Kaplan-Meyer analysis for survived
and free from neurological events does not diﬀer between
patients with and without restenosis conﬁrming the benign
course of in-stent restenosis [20]a so c c u rf o rr e s t e n o s i sa f t e r
CEA [21]. Although there are few and often asymptomatic
signiﬁcant (>80%) in-stent restenosis, probably they will
increase in the next time and may became, in future, a
clinical problem due to the widespread application of CAS
[22]. Concerning to the treatment of in-stent restenosis,
angioplasty has been recently recommended as the primary
approach to hyperplastic lesions with repeat stenting in cases
of suboptimal results [23]. Although further experiences in
carotidarteryrestenosisafterstentarenecessarytoformulate
standardized approaches, in our limited experience, the
endovascular treatment of restenosis seems to be safety and
when it is not feasible, surgical treatment can be considered
[24].
According to previous studies, restenosis occurs prefer-
entially in the ﬁrst year from the endovascular procedure (20
outof 23 in the ﬁrst12 months) and reduces its prevalencein
the subsequent years. It is generally accepted that the major
cause of restenosis and of its benign course is neointimal
hyperplasia with smooth muscle cells proliferation [25] that
prevailed in the ﬁrst 12 months after CEA [26].
Speciﬁcriskfactorsinthedevelopmentofrestenosisafter
CAS remains to be elucidated: some studies have identiﬁed
advanced age [27, 28], hyperglycemia [27, 29], smoke [27]
and previous CEA [30]. In our study group, out of all
the evaluated clinical radiological and procedural variables,
multivariate analysis reveal that the residual stenosis after
CAS is a stronger predictor of restenosis with a consistent
increased risk of restenosis (1.091 per % unit of residual
stenosis). Suboptimal technical results after CAS was previ-
ously described as clinical predictor of restenosis in the ﬁrst
six months of followup [31]a n das m a l lp o s tp r o c e d u r a l
stent dimension evaluated with intravascular ultrasound
imaging has been demonstrated to be associated with a
higher risk of restenosis also in carotid artery stenting [32].
Although larger studies with long term followup do not
reveal [33] this radiological variable as predictor, recently
suboptimal result with residual stenosis has been reported as
a restenosis predictor [34] Carotid neointimal proliferation
and stent auto-expansion have counteracting eﬀects: the
ﬁrst one predominates during the ﬁrst year after stenting,
whereas the latter in the subsequent year [35]. We may
suppose that in some cases, unexpanded carotid stent could
imbalance these complex counteracting eﬀects in favour of
neointimal proliferation inducing post procedural stenosis
and a following long term restenosis.
Our results suggest that post procedural stenosis has a
higher risk of restenosis and it conﬂicts with the opinion
that to pursue a perfect angiographic result after CAS is not
necessary [36]. Nevertheless, small post procedural lumen
dimension as a restenosis predictor have to be considered
with caution and have not to induce an opposite aggressive
behaviour because it is known that high post dilation
pressures increase the risk of embolization and neointimal
proliferation [37].
To our knowledge the implantation of multiple stents as
a restenosis predictor after CAS has been mentioned in a
brief report [28]. In our experience, similarly to the results of
the coronary stenting, by both univariate [38] and multiple
logistic regression analysis [39] the number of stents per
lesion is a signiﬁcant variable and independent predictor of
restenosis.Probablythehigherrisk ofin-stentrestenosis may
be due to a larger surface area covered with stent material
or to the overlapped edges of the stent inducing a more
enunciated intimal hyperplasia.
Ourstudyidentifyotherclinicalvariableswithalessrele-
vant inﬂuence on restenosis such as diabetes and neoplasms.
The role of diabetes has been described as a predictor of
carotid [27, 28] and coronary in-stent restenosis [40]a n dStroke Research and Treatment 5
may be due to smooth muscle cell proliferation common in
diabeticpatients[41].Theroleofneoplasmsintherestenosis
occurrence is prone to speculative interpretations, in fact
a series of cell proliferation regulatory pathways have been
associated with plaque progression, stenosis and restenosis
after angioplasty as well as in cancer progression [42].
The main limitations of the study are the small number
of patients and events sourcing by a single centre study.
However the detection of independent predictors after CAS
thatevokethepredictorsaftercoronarystenting[43],maybe
useful to be largely studied in prospective randomized trials.
In our CAS experience encouraging long term results
seem to derive from both neurological event free rate and
restenosis incidence. Because of residual stenosis after CAS
is a strongest independent predictor of restenosis, adequate
recanalization of the treated vessel seems an important
goal to limit the development of restenosis. Multiple stents
deployment and with less evidence, diabetes or neoplasm
have to be considered to facilitate in-stent restenosis after
CAS.
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